Barclays PLC Purchases 21,060 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Barclays PLC lifted its position in OptimizeRx Co. (NASDAQ:OPRX) by 358.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,934 shares of the company’s stock after buying an additional 21,060 shares during the quarter. Barclays PLC owned about 0.15% of OptimizeRx worth $208,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Quest Partners LLC lifted its holdings in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the last quarter. Connors Investor Services Inc. lifted its holdings in OptimizeRx by 15.1% in the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in OptimizeRx in the 2nd quarter worth approximately $282,000. Finally, Rhumbline Advisers lifted its holdings in OptimizeRx by 9.2% in the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after purchasing an additional 2,658 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on OPRX shares. Stephens began coverage on OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Lake Street Capital reiterated a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th. JMP Securities cut their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday, November 14th. Stifel Nicolaus cut their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, Royal Bank of Canada cut their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.19.

OptimizeRx Price Performance

Shares of OPRX stock opened at $5.57 on Tuesday. The stock’s fifty day moving average is $5.15 and its 200-day moving average is $7.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $102.60 million, a PE ratio of -4.19 and a beta of 1.36. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $16.65.

Insider Activity

In related news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by insiders.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.